Premium
Adriamycin‐vitamin E combination therapy for treatment of prostate adenocarcinoma in the NB rat model
Author(s) -
Nesbitt John A.,
Smith Jeffery,
McDowell Gladstone,
Drago Joseph R.
Publication year - 1988
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930380416
Subject(s) - medicine , prostatic adenocarcinoma , prostate adenocarcinoma , adenocarcinoma , prostate , oncology , prostate cancer , urology , cancer
Adriamycin used in combination with vitamin E (Tocopherol) was evaluated in the treatment of Nb rat prostate adenocarcinoma. Vitamin E has been shown to enhance the growth‐inhibitory effects of adriamycin on human prostatic carcinoma cells in vitro. The adriamycin‐vitamin E treatment groups had the lowest average final tumor volume, but the mortality rate was 57% (17/30). These results suggest that vitamin E may play a role in enhancing the cytotoxic effects of adriamycin, but may not have any protective effect on normal cells as previously suggested through in vitro methods.